• Survey of 800+ patients globally underscores key challenges in accessing care, understanding biomarker testing, post-diagnosis emotional health and patient support
• GSK's Your Cancer Is Our Challenge will raise awareness of barriers and inspire future solutions to address them, beyond treatment

GSK plc (LSE/NYSE: GSK) today announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecologic cancers may experience. The survey, which was conducted by The Harris Poll and included responses from 818 participants from 10 countries who have been affected by endometrial, ovarian, cervical, vaginal, and/or vulvar cancers, found that 73% of patients did not feel empowered to overcome their cancers, and 78% of patients experienced challenges in accessing the treatment they need. The survey also identified opportunities for more comprehensive patient support, such as greater understanding of biomarker testing to inform treatment and emotional health resources.

This survey supports the launch of Your Cancer Is Our Challenge, GSK's multi-year, integrated initiative that aims to uncover and address gaps and barriers faced by patients with gynaecologic cancers and create solutions to drive progress—beyond treatment. These results represent the first stage of the programme; the second stage will announce specific actions informed by these findings to help better assist patients throughout their cancer journey.

Nina Mojas, Senior Vice President, Oncology Global Product Strategy, GSK, said: "At GSK, we continue to develop new therapies for patients with gynaecologic cancers, yet we know there are also significant needs that treatment alone won't address. The Your Cancer Is Our Challenge programme is using real-world insights to show gaps and barriers in care, knowledge and support that will inspire future solutions that aim to address those challenges and improve patients' lives."

Jennifer Garam, ovarian cancer survivor, said: "Being diagnosed with a gynaecologic cancer, such as ovarian cancer, impacts every aspect of your life. Beyond medical treatment, patients with gynaecologic cancers have many other needs that also have to be addressed, such as access to information, resources and the right psychosocial support. GSK's Your Cancer Is Our Challenge is an important step forward in identifying these key challenges and barriers—so they can be addressed and overcome."

Survey findings revealed unmet needs and barriers in patient care, offering actionable insights to improve the patient experience, based on the following overarching themes:

• Gaps in knowledge related to treatment:
  • Most respondents (89%) wanted to know more about what types of test options (e.g., biomarker testing, tumour genetic testing, genomic profile testing, etc.) are available to inform their treatment.
• Emotional burden of treatment and care:
  • While 91% of patients who received treatment felt they are receiving the best treatment possible for their gynaecologic cancer, 73% of all patients surveyed did not feel empowered to overcome their diagnosis.
• Barriers to care:
  • 78% of patients reported challenges in accessing the treatment they need, with appointment availability (36%) being a top barrier. Common reasons for challenges in attending appointments were: the need to manage day-to-day responsibilities (25%), difficulty managing the required paperwork (24%), or not feeling well enough to leave the house (23%).
• Low utilisation of patient support groups:
  • Participation in support groups was low, with only 25% of respondents citing they participated in a support group, while even fewer (14%) stated that they had found a cancer support group that had been helpful in navigating their experience.

Mary Eiken, Chief Executive Officer, International Gynecologic Cancer Society, said: "These findings highlight the pressing need for better access to comprehensive care and clear information for patients with gynaecologic cancers, as many face barriers beyond treatment—such as understanding their options, accessing meaningful support networks and managing the daily realities of their diagnosis. GSK's Your Cancer Is Our Challenge initiative is an important programme working to address these barriers and improve support available to patients with gynaecologic cancers worldwide."

More information about Your Cancer Is Our Challenge and the survey is available in this article. In addition, a detailed list of key survey findings is available on GSK.com.

About the Your Cancer Is Our Challenge survey

The research was conducted online by The Harris Poll on behalf of GSK among 818 adult women ages 18+ who have been diagnosed with ovarian, uterine/endometrial/womb, cervical, vulvar, and/or vaginal cancer, residing in Brasil (n=51), France (n=100), Germany (n=105), Greece (n=50), Italy (n=105), Poland (n=50), Spain (n=100), Türkiye (n=50), the United Kingdom (n=105), and the United States (n=102). The survey was conducted 13 March 2024 – 12 May 2024. Individual country results are not weighted and therefore only representative of the individuals surveyed. Total global data are weighted across countries equally. For this study, the total sample data are accurate to within + 3.6 percentage points using a 95% confidence level. This credible interval will be wider among subsets of the surveyed population of interest.

GSK in oncology

Oncology is an emerging therapeutic area for GSK where we are committed to maximising patient survival with a current focus on haematologic malignancies, gynaecologic cancers and other solid tumours through breakthroughs in immuno-oncology and tumour-cell targeting therapies.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q3 Results for 2024.